On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


As Tech Data Industry Takes $55 Billion Hit, SRAX Inc. (NASDAQ: SRAX) Sidesteps the Bullet by Doing What’s Right

  • New privacy laws in California place SRAX ahead of the competition
  • Privacy has always been a consumer right for SRAX
  • Building a reliable, opted-in consumer dataset has long-term, recurring revenue potential for SRAX

SRAX Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, has developed a consumer-managed data marketplace where people can own and earn from their data. As new privacy laws come into play in California, Los Angeles-based SRAX is already ahead of the competition.

BIGtoken, built by SRAX, offers a secure and transparent environment for consumers to own and earn from their data. Long before California law makers were writing legislation that valued the privacy of individuals over the agenda of big players (i.e. Facebook, Google, Amazon), SRAX was putting the consumer in the driver’s seat. Founded in 2010, the company has sought from the beginning to provide highly valued, consumer-powered data that reveals brands’ core consumers. By providing the consumer with essential key control, the company has unlocked the true value of data.

While other companies are adjusting budgets to cover the cost of compliancy to a new California law by January 1, 2020, BIGtoken has already sidestepped the legal data issue because it requests users’ permission for data sharing when those users initially sign up for the platform. BIGtoken puts control in the hands of the consumer by providing the right to privacy, awareness and choice from the get-go (http://ibn.fm/KG5zt). Once users sign up, they are able to determine and make decisions on how much of their information is shared and to whom. For SRAX, privacy has always been a right.

Doing the right thing from day one has placed SRAX a step ahead in the industry. Competitors in digital marketing and consumer data management will be spending up to $55 billion to comply with the California Consumer Privacy Act (CCPA) (http://ibn.fm/LtGNZ). The bill gives California residents the right to be informed about how companies gather and use their data, an ideal that is an integral component of BIGtoken’s core mission. BIGtoken has been building consumers’ trust, resulting in an increase of consumer opted-in data made available to brands, making that data far more valuable than information collected through data mining.

SRAX is building reliable, opted-in consumer data set that will have a long-term recurring revenue stream. As consumers become more aware of the value of their data, they naturally expect to be compensated for it. The larger social media platforms such as Facebook, Twitter, and Snapchat are experiencing consumer backlash as questions are being asked and more privacy laws are going into effect.

The CCPA appears to be only the beginning as consumers become more aware of their data rights and demand more of those entrusted with it. Privacy laws at both the state and federal level will continue to change and impact the way marketers reach consumers. As consumers become more empowered and informed, SRAX will continue to meet their high expectations.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.